SAN DIEGO. -- REVA Medical, Inc. ("REVA" or the "Company") is pleased to announce that a clinical update on patients from its RESTORE pilot study is being presented at the Transcatheter Therapeutics Conference, the world's largest interventional cardiology meeting, which is being held this week in Miami, Florida. Reporting on the results is Dr. Ricardo Costa from the Dante Pazzanese Institute de Cardiologie, a leading enrollment center for the trial located in Sao Paulo, Brazil.

A total of 22 patients were implanted with the Company's ReZolve^(R) scaffold at six hospitals in four countries. The first patient treated is 10 months post-implant and remains event free. To date, there have been no reported blood clots (thrombosis), no reported incidences of myocardial infarction (heart attack), and a low rate of major adverse coronary events.

"We continue to be encouraged with the results in the RESTORE pilot study," commented REVA's CEO, Bob Stockman. "One-year results on a subset of patients, which will include angiographic follow-up to evaluate the performance of the scaffold, will be announced at the EuroPCR conference to be held next May in Paris, France."

Source: REVA Medical, Inc.